We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Statera BioPharma Inc (CE) | USOTC:STAB | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 6,704 | 00:00:00 |
UNITED STATES | ||
SECURITIES AND EXCHANGE COMMISSION | ||
Washington, D.C. 20549 | ||
FORM 25 | ||
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. | ||
Commission File Number 001-32954 | ||
Issuer: | Statera Biopharma, Inc. |
Exchange: | Nasdaq Stock Market LLC |
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
Address: | 73 High Street Buffalo, NEW YORK 14203 |
Telephone number: | 716-849-6810 |
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) |
Common Stock |
(Description of class of securities) |
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration: |
o 17 CFR 240.12d2-2(a)(1) |
o 17 CFR 240.12d2-2(a)(2) |
o 17 CFR 240.12d2-2(a)(3) |
o 17 CFR 240.12d2-2(a)(4) |
x Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1 |
o Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange. |
Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person. |
2023-03-03 | By | Aravind Menon | Hearings Advisor | |
Date | Name | Title | ||
1 | Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions. |
1 Year Statera BioPharma (CE) Chart |
1 Month Statera BioPharma (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions